Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
American Stroke Association, Feb. 7-9
Feb 20, 2024
The conference featured presentations that emphasized basic, clinical and translational medicine and provided insight into the prevention, management and treatment of stroke.
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
AI may help predict mortality in dementia patients
Mar 05, 2024
The prediction was feasible across time frames using certain clinical features.
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Vitamin D supplementation may cut dementia incidence
Mar 08, 2023
Any vitamin D supplement exposure was associated with a 40% lower dementia incidence.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
Gantenerumab does not slow clinical decline in early Alzheimer’s disease
Nov 16, 2023
Two trials show a lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.